InvestorsHub Logo
Post# of 252311
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: mskatiescarletohara post# 33492

Friday, 09/01/2006 1:34:02 PM

Friday, September 01, 2006 1:34:02 PM

Post# of 252311
mskatiescarletohara,

Thanks for the reply. PPHM is a company I wasn't familiar with. It seems like half the biotech's are working on something in Hep. C.

Which PI's are you referring too, the one's in clinical trials? ABT's Kaletra is the only other PI I'm aware of that is being testing in combo with other HCV compounds.
I was thinking a few years out if there are 3 PI's approved (or earlier in the clinic if 1 is approved and a company wants to do something with their PI). Not a scientist but curious if there may be some advantage to combining 2 PI's with different resistence against variants or if some scientific reason (at this early stage) why it wouldn't make sense to try 2 different PI's together



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.